The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments

http://www.prnewswire.com/news-relea...-78151902.html

NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced $1.5 million in total awards to six research teams working to develop potentially disease-modifying therapies for Parkinson's disease. The funding was awarded under the Novel Approaches to Drug Discovery for Parkinson's Disease program, made possible by funding from Elan Corporation, plc (NYSE: ELN), a neuroscience-based biotechnology company.

The Novel Approaches program is an important component of MJFF's overall strategy of providing critical resources to under-funded areas of the drug development pipeline. Novel Approaches seeks to advance the development of therapeutic targets that already have some promising initial data, while engaging industry partner Elan as a potential follow-on funder for those projects with the greatest potential to bring new, transformative treatments to people living with PD.